Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.

• DOI: 10.1200/jco.2014.32.15_suppl.3600
• Publication Date: 2019-01-03T22:31:06Z
• Authors: Volker Heinemann; Dominik Paul Modest; Ludwig Fischer vo...; Thomas Decker; Alexander Kiani; Ursula Vehling-Ka...; Salah-Eddin Al-Ba...; Tobias Heintges; Christian A. Lerc...; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Swantje Held; Clemens Albrecht ...; Andreas Jung; Thomas Kirchner; Sebastian Stintzing
• Keywords: FOLFIRI; Splenic flexure; Progression-free survival; Clinical endpoint

3600 Background: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type mCRC patients. We analyzed the efficacy dependent on gender and primary tumor location within RAS population (n=342). Methods: Primary was defined as follows: right sided CRC (RCRC): coecum to hepatic flexure; left (LCRC): splenic flexure rectum. Colon transversum tumors (n=9) were excluded. Differences response (ORR) survival (PFS/OS) both treatment arms calculated using two-sided Fisher´s exact logrank test, respectively. Results: In wise comparison LCRC shows better results (ORR, PFS OS) when RCRC especially arm (Table). Female has a trend towards lower rates, shorter OS male Conclusions: MCRC is heterogeneous disease. Treatment depends patients' gender. Effects more prominent patients receiving where are favored. + Cetuximab n=167 Bevacizumab n=166 n=30 n=137 p n=39 n=127 ORR (%) 46.7 70.1 0.019# OR: 2.7 48.7 62.2 0.14# 1.7 (mo) 6.9 10.8 <0.0001* HR: 0.35 8.8 10.5 0.065* 0.69 16.1 38.7 0.26 22.7 28.0 0.034* 0.63 female n=44 n=123 n=54 n=112 54.5 69.9 0.095# 1.9 55.6 60.7 0.61# 1.24 9.2 10.6 0.005* 0.60 9.1 10.3 0.051* 0.70 27.9 36.4 0.12* 0.71 25.9 24.8 0.8* 1.05 Abbreviations: Bev, bevacizumab; Cet, cetuximab; OR, Odds ratio; HR, hazard mo, months. *= p; #= Fisher's p.